326 related articles for article (PubMed ID: 23270484)
21. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.
Prins RM; Wang X; Soto H; Young E; Lisiero DN; Fong B; Everson R; Yong WH; Lai A; Li G; Cloughesy TF; Liau LM
J Immunother; 2013 Feb; 36(2):152-7. PubMed ID: 23377664
[TBL] [Abstract][Full Text] [Related]
22. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
Lesterhuis WJ; Schreibelt G; Scharenborg NM; Brouwer HM; Gerritsen MJ; Croockewit S; Coulie PG; Torensma R; Adema GJ; Figdor CG; de Vries IJ; Punt CJ
Cancer Immunol Immunother; 2011 Feb; 60(2):249-60. PubMed ID: 21069321
[TBL] [Abstract][Full Text] [Related]
23. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.
Okada H; Lieberman FS; Walter KA; Lunsford LD; Kondziolka DS; Bejjani GK; Hamilton RL; Torres-Trejo A; Kalinski P; Cai Q; Mabold JL; Edington HD; Butterfield LH; Whiteside TL; Potter DM; Schold SC; Pollack IF
J Transl Med; 2007 Dec; 5():67. PubMed ID: 18093335
[TBL] [Abstract][Full Text] [Related]
24. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
[TBL] [Abstract][Full Text] [Related]
25. Generation of immature autologous clinical grade dendritic cells for vaccination of cancer patients.
Toungouz M; Quinet C; Thille E; Fourez S; Pradier O; Delville JP; Velu T; Lambermont M
Cytotherapy; 1999; 1(6):447-53. PubMed ID: 20426545
[TBL] [Abstract][Full Text] [Related]
26. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
27. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
Mehrotra S; Britten CD; Chin S; Garrett-Mayer E; Cloud CA; Li M; Scurti G; Salem ML; Nelson MH; Thomas MB; Paulos CM; Salazar AM; Nishimura MI; Rubinstein MP; Li Z; Cole DJ
J Hematol Oncol; 2017 Apr; 10(1):82. PubMed ID: 28388966
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
[TBL] [Abstract][Full Text] [Related]
29. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
J Neurooncol; 2016 Dec; 130(3):517-527. PubMed ID: 27624914
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H
Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
[TBL] [Abstract][Full Text] [Related]
31. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells.
Mackensen A; Herbst B; Chen JL; Köhler G; Noppen C; Herr W; Spagnoli GC; Cerundolo V; Lindemann A
Int J Cancer; 2000 May; 86(3):385-92. PubMed ID: 10760827
[TBL] [Abstract][Full Text] [Related]
32. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.
Banchereau J; Ueno H; Dhodapkar M; Connolly J; Finholt JP; Klechevsky E; Blanck JP; Johnston DA; Palucka AK; Fay J
J Immunother; 2005; 28(5):505-16. PubMed ID: 16113607
[TBL] [Abstract][Full Text] [Related]
33. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors.
Toungouz M; Libin M; Bulté F; Faid L; Lehmann F; Duriau D; Laporte M; Gangji D; Bruyns C; Lambermont M; Goldman M; Velu T
J Leukoc Biol; 2001 Jun; 69(6):937-43. PubMed ID: 11404379
[TBL] [Abstract][Full Text] [Related]
34. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.
Trepiakas R; Pedersen AE; Met O; Hansen MH; Berntsen A; Svane IM
Vaccine; 2008 Jun; 26(23):2824-32. PubMed ID: 18450338
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma.
Lau R; Wang F; Jeffery G; Marty V; Kuniyoshi J; Bade E; Ryback ME; Weber J
J Immunother; 2001; 24(1):66-78. PubMed ID: 11211150
[TBL] [Abstract][Full Text] [Related]
36. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides.
Liu KJ; Wang CC; Chen LT; Cheng AL; Lin DT; Wu YC; Yu WL; Hung YM; Yang HY; Juang SH; Whang-Peng J
Clin Cancer Res; 2004 Apr; 10(8):2645-51. PubMed ID: 15102666
[TBL] [Abstract][Full Text] [Related]
37. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
38. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy.
Ueda Y; Itoh T; Fuji N; Harada S; Fujiki H; Shimizu K; Shiozaki A; Iwamoto A; Shimizu T; Mazda O; Kimura T; Sonoda Y; Taniwaki M; Yamagishi H
Cancer Immunol Immunother; 2007 Mar; 56(3):381-9. PubMed ID: 16830156
[TBL] [Abstract][Full Text] [Related]
39. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]